Decompensated Heart Failure Management

Definition

The 2026 ESC guideline replaced "acute heart failure" with "decompensated heart failure" — acute or gradual onset of symptoms and signs severe enough to require urgent attention — and divided it into four clinical categories: decompensated left-sided heart failure, decompensated right-sided heart failure, acute pulmonary oedema, and cardiogenic shock. (sources/HF-ESC-2026, rating: very high)

This page owns the first three. Cardiogenic shock is summarised at the end and managed on concepts/Cardiogenic-Shock. The chronic syndrome, its phenotypes and its foundational therapy are on entities/Heart-Failure.

The change of terminology is not cosmetic: "acute" described a tempo, whereas "decompensated" describes a patient with established heart failure whose compensation has failed, which is why the pathway leads back into optimisation of chronic therapy rather than stopping at decongestion.

Key Concepts

Diagnosis and Risk Assessment

• Rule-out thresholds: NT-proBNP <300 pg/mL, BNP <100 pg/mL, MR-proANP <120 pg/mL. (sources/HF-ESC-2026, rating: very high)
• Age-banded rule-in: NT-proBNP >450 pg/mL below 50 years, >900 at 50–74, >1800 above 74.
• NT-proBNP >5000 pg/mL implies very high risk and generally warrants admission.
• Natriuretic peptides are lower in obesity and higher in atrial fibrillation and renal impairment; interpret against the clinical picture rather than as a standalone gate.

The Four Clinical Categories

The categories overlap and patients migrate between them; a patient admitted with left-sided congestion who becomes hypotensive has moved category, which changes management more than any drug adjustment.

Decongestion — First-Line Therapy

• Intravenous loop diuretics — Class I/A, the single intervention every other decision waits on. (sources/HF-ESC-2026, rating: very high)
• A satisfactory diuretic response is defined objectively: urine sodium ≥70 mEq/L at 2 hours, or urine output ≥100 mL/h over the first 6 hours. This is the bedside test of whether the diuretic is working, and it should be measured rather than assumed.
• IV acetazolamide or oral hydrochlorothiazide — Class IIa/B1, new in 2026 on ADVOR and CLOROTIC. Both improve decongestion; neither has shown a hard-endpoint benefit, so they are adjuncts to a failing loop diuretic, not substitutes for it. (sources/acetazolamide-acutehf-nejm-2022, rating: high)
• Urinary-sodium-guided diuretic therapy — Class IIb/B1, on PUSH-AHF and ENACT-HF: the dose is titrated to the measured urine sodium rather than to a fixed regimen.
• Monitor blood pressure, pulse, input and output, oxygen saturation and respiratory rate every 30–60 minutes during stabilisation, with daily weights and renal function.

When Diuretics Are Not Enough

Loop diuretic resistance arises from the braking phenomenon, distal tubular hypertrophy and reduced tubular secretion; it is why the response is measured in urine sodium rather than in litres. Escalation runs: increase the loop dose → add a distal-acting thiazide for sequential nephron blockade → acetazolamide for proximal tubular blockade → ultrafiltration or renal replacement for true diuretic failure.

Full mechanism, the ADVOR and CLOROTIC evidence, and the pharmacology behind each step are on concepts/Diuretic-Resistance. The kidney–heart interaction driving the failing diuresis is on concepts/Cardiorenal-Syndrome.

Vasodilators, Inotropes and Opiates

All three are weak recommendations in 2026, and the direction of the guideline is that none should be routine: (sources/HF-ESC-2026, rating: very high)

• Vasodilators — Class IIb/C, only where systolic pressure is >110 mmHg. Preload and afterload reduction in the hypertensive, congested patient.
• Inotropes — Class IIb/C, reserved for hypoperfusion with low output; they increase oxygen demand and provoke arrhythmia.
• Vasopressors — Class IIb/C, norepinephrine first-line, for hypotension threatening organ perfusion.
• Routine opiates — Class III/C. No benefit, and worse outcomes.

Decompensated Right-Sided Heart Failure

The category with no prior page in the wiki. Predominantly systemic venous congestion — raised JVP, peripheral and sacral oedema, ascites, hepatic congestion and often a congested, underperfused kidney — arising from RV dysfunction, pulmonary hypertension, tricuspid disease or a left-sided problem transmitted backwards.

• Distinguish the dominant side before treating. A congested patient with a normal PCWP and a high right atrial pressure has a different problem from one with left-sided congestion, and fluid removal tolerated by the former may precipitate hypotension in the latter.
• Fluid strategy is tailored, not uniform: the LV-dominant patient is unloaded; the RV-dominant patient is at risk of becoming preload-dependent, so diuresis must be balanced against perfusion.
• Venous congestion itself impairs renal function — the rise in renal venous pressure is part of why diuresis appears to fail in these patients, and why decongestion often improves rather than worsens renal function.
• See concepts/Right-Ventricular-Failure for the mechanism and concepts/Cardiorenal-Syndrome for the kidney.

Cardiogenic Shock

The fourth category. Hypoperfusion from primary cardiac dysfunction, with no specific blood-pressure threshold and lactate >2 mmol/L as the biochemical criterion. Management — SCAI staging, vasopressors and inotropes, revascularisation, temporary and durable mechanical support, and weaning — is on concepts/Cardiogenic-Shock.

What belongs here is the recognition step: decompensated heart failure becomes shock when perfusion fails, not when pressure falls. A normotensive patient with rising lactate, oliguria and cool extremities has crossed into the fourth category.

In-Hospital Initiation Before Discharge

• SGLT2 inhibitor started in hospital after initial stabilisation — Class I/B1, new in 2026 on EMPULSE and SOLOIST-WHF. (sources/HF-ESC-2026, rating: very high)
• Early empagliflozin in hospitalised decompensated heart failure produced clinical benefit across death, heart-failure events and KCCQ — win ratio 1.36 (95% CI 1.09–1.68; P=0.0054) — independent of ejection fraction and diabetes status. (sources/HF-update-ESC-2023, rating: very high)
• Rapid initiation and up-titration of foundational medical therapy before discharge, with frequent visits over the first six weeks — Class I/B2 (STRONG-HF). Intensive oral therapy started pre-discharge reduced heart-failure readmission or death at 180 days from 23.3% to 15.2% (aRR 0.66; P=0.0021); readmissions alone fell (aRR 0.56), all-cause death alone did not.
• STRONG-HF calls the traditional sequential approach "suboptimal" and prefers simultaneous implementation, but the guideline declines to specify a number or sequence of drug classes, because no RCT has tested one.

Transition and the Six-Week Window

• Follow-up visits should monitor congestion, blood pressure, heart rate, NT-proBNP, potassium and eGFR — the six variables that determine whether up-titration is safe.
• The first six weeks after discharge carry the highest risk of readmission and death, which is why the guideline locates up-titration there rather than in the outpatient clinic months later.
• Handover to the chronic pathway — phenotype, foundational therapy and the annual review structure — is on entities/Heart-Failure; rehabilitation is on concepts/Cardiac-Rehabilitation-HF.

Contradictions / Open Questions

• "Decompensated" replaced "acute" without a trial. The retitled classification is a conceptual reorganisation, not an evidence-based one, and no study has compared outcomes under the two framings. (sources/HF-ESC-2026, rating: very high)
• Acetazolamide and hydrochlorothiazide improve decongestion but not hard endpoints. ADVOR increased successful decongestion at day 3 (42.2% vs 30.5%) without reducing death or rehospitalisation at 3 months, yet both drugs now carry a IIa/B1 recommendation — a recommendation graded on a surrogate. (sources/acetazolamide-acutehf-nejm-2022, rating: high)
• The diuretic targets are surrogates. Urine sodium ≥70 mEq/L at 2 h and ≥100 mL/h at 6 h are reproducible and clinically sensible, but no trial has shown that titrating to them improves outcomes.
• STRONG-HF's result is not decomposable into its parts. The intervention bundled pre-discharge initiation, rapid up-titration and frequent follow-up; which component drove the 8-percentage-point absolute reduction is unknown, and the guideline explicitly declines to specify a sequence for that reason.
• The four categories are descriptive, not validated. No trial has randomised patients by category, and patients move between them within hours — the category a patient is assigned depends on the moment of assessment.
• Vasodilators, inotropes and vasopressors all sit at IIb/C, meaning the guideline is neutral across the three, while clinical practice varies considerably. The hypertensive patient with pulmonary oedema — the archetypal candidate for nitrates — has no strong recommendation.
• Opiates are now Class III/C despite decades of routine use for dyspnoea in pulmonary oedema; the wiki's operational protocol still lists morphine 2–5 mg, so the bedside pathway and the guideline disagree. (sources/Handbook-HA-2024)
• The right-sided category is the thinnest in the evidence base. It exists in the classification but the recommendations largely concern congestion in general, and RV-specific decompensation management is extrapolated.
• The transition point from decompensated to chronic is undefined, as is the timing of de-escalation of intravenous therapy.
• Decongestion versus perfusion remains the central unresolved trade-off in right-sided and biventricular failure: there is no validated measure of how much volume a given patient can lose before output falls.

Connections

• The chronic syndrome: entities/Heart-Failure — phenotypes, staging, foundational therapy
• Cardiogenic shock: concepts/Cardiogenic-Shock — the fourth category, in full
• Decongestion mechanism: concepts/Diuretic-Resistance · concepts/Cardiorenal-Syndrome
• Right-sided disease: concepts/Right-Ventricular-Failure
• Precipitants and mimics: entities/Acute-Coronary-Syndrome · entities/Atrial-Fibrillation · concepts/Aortic-Stenosis · concepts/Tricuspid-Regurgitation · concepts/Pulmonary-Hypertension
• Pharmacology: entities/Sacubitril-Valsartan · entities/Finerenone · concepts/SGLT2-Inhibitors-in-CKD · concepts/Cardiac-Glycosides-in-HFrEF
• After discharge: concepts/Cardiac-Rehabilitation-HF · concepts/Remote-Patient-Monitoring

Sources

• sources/HF-ESC-2026
• sources/HF-update-ESC-2023
• sources/Handbook-HA-2024
• sources/acetazolamide-acutehf-nejm-2022